Synlogic
OTC: SYBXCambridge, US · Founded 2014 · Delaware corporation · 19 employees on LinkedIn · 7 known investors
Synlogic develops synthetic biology-based biotherapeutics that use engineered living organisms to treat diseases. The company applies synthetic biology approaches to design programmable therapeutic candidates for patients.
Founders & leadership
BC
Bharatt ChowrirainPresident2015–2017
MS
Michael SheahanExecutive
JC
Jose Carlos Gutierrez-RamosinExecutive
PM
Paul MillerinChief Scientific Officer2014–2019
AB
Aoife BrennaninExecutive
TS
Todd ShegoginCFO2016–2019
DG
DANIEL GEFFKENExecutive
Board
EM
CK
AM
Ankit MahadeviaBoard director
PB
NL
Nick LeschlyBoard director
Investors · 7
Reported raises · per SEC filings
Form D private placements$77M disclosed across 4 rounds · 2014–2017
▶$42MraisedMay 2017 · 16 investors · BiotechnologyRule 506(b)
▶$42MraisedMay 2017 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul MillerExecutive Officer
- Peter BarrettDirector
- Chau KhuongDirector
- Aoife BrennanExecutive Officer
- Nick LeschlyDirector
- Lewis GeffenExecutive Officer
- Jose Carlos Gutierrez-RamosExecutive Officer, Director
- Ed MathersDirector
- Todd ShegogExecutive Officer
- Offering amount
- $42M
- Amount sold
- $42M
- First sale
- May 2017
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$17.1MraisedFeb 2016 · 3 investors · BiotechnologyRule 506(b)
▶$17.1MraisedFeb 2016 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ed MathersDirector
- Chau KhuongDirector
- Bharatt ChowriraExecutive Officer
- Ankit MahadeviaDirector
- Michael SheahanExecutive Officer
- Peter BarrettDirector
- Jose Carlos Gutierrez-RamosExecutive Officer, Director
- Lewis GeffenExecutive Officer
- Offering amount
- $17.1M
- Amount sold
- $17.1M
- First sale
- Feb 2016
- Incorporated
- Limited Liability Company, Delaware, 2015
- Federal exemptions
- 06b
▶$13.9MraisedFeb 2016 · 2 investors · BiotechnologyRule 506(b)
▶$13.9MraisedFeb 2016 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jose Carlos Gutierrez-RamosExecutive Officer, Director
- Ed MathersDirector
- Lewis GeffenExecutive Officer
- Bharatt ChowriraExecutive Officer
- Michael SheahanExecutive Officer
- Peter BarrettDirector
- Chau KhuongDirector
- Ankit MahadeviaDirector
- Offering amount
- $40.6M
- Amount sold
- $13.9M
- First sale
- Feb 2016
- Incorporated
- Limited Liability Company, Delaware, 2015
- Federal exemptions
- 06b
▶$4MraisedJul 2014 · 2 investors · BiotechnologyRule 506(b)
▶$4MraisedJul 2014 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- DANIEL GEFFKENExecutive Officer
- ED MATHERSDirector
- PETER BARRETTDirector
- ANKIT MAHADEVIAExecutive Officer, Director
- LEWIS GEFFENExecutive Officer
- Offering amount
- $29.4M
- Amount sold
- $4M
- First sale
- Jul 2014
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Synlogic went on to found or lead other companies.
Competitors · 5
by search overlap
Abiologics30 shared keywordsAbiologics uses computational design tools to create protein-inspired molecules called Synteins, engineered to avoid the vulnerabilities of natural protein medicines while retaining biological function. The company develops these molecules as a new class of therapeutics with the aim of advancing candidates toward clinical development.
Bioworld21 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Sentynl21 shared keywordsA biopharmaceutical company developing novel medicines for rare diseases, serving patients and caregivers from early detection through therapeutic intervention.
Senti Biosciences19 shared keywordsSenti Bio develops cell and gene therapies for cancer and difficult-to-treat diseases using synthetic biology and engineered Gene Circuits to enhance precision, control, and selectivity in targeting tumor cells. The company is a clinical-stage biotech firm leveraging proprietary platform technology across multiple cell types and modalities.
Syneos Health18 shared keywordsSyneos Health is a fully integrated biopharmaceutical solutions organization that provides clinical, medical affairs, and commercial services to help pharmaceutical companies accelerate market access and patient outcomes.
Companies competing with Synlogic for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Synlogic do?
- Synlogic develops synthetic biology-based biotherapeutics that use engineered living organisms to treat diseases. The company applies synthetic biology approaches to design programmable therapeutic candidates for patients.
- Who are Synlogic's investors?
- Synlogic's investors include Atlas Venture, New Enterprise Associates (NEA), NSG Ventures, Pfizer Venture Investments, Sofinnova Ventures, Solasta Ventures, OrbiMed.
- How much funding has Synlogic raised?
- Synlogic has disclosed $77M raised across 4 rounds.
- Where is Synlogic headquartered?
- Synlogic is headquartered in Cambridge, US.